Matthew L Freedman

9PUBLICATIONS
41CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer diagnosisPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 03, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.

Douglas M Dahl, Joseph P Rodgers, William U Shipley

|May 07, 2022
Phase II Study of Cabozantinib in Patients With Bone Metastasis.

Edwin Choy, Gregory M Cote, M Dror Michaelson

|Feb 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.

Bradley A McGregor, Wanling Xie, Elio Adib

|Aug 28, 2021
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.

Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos

|May 19, 2021
Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.

Daniel E Lage, M Dror Michaelson, Richard J Lee

|Apr 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.

Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos

Pageof 2

Frequent Collaborators

5 joint publications

Toni K Choueiri

3 joint publications

Amin H Nassar

2 joint publications

Pier Vitale Nuzzo

2 joint publications

Jacob E Berchuck